The ESTxENDS Trial- Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation-extension of Follow-up

Overview

Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. Only two rigorous randomized controlled trials (RCTs) on the efficacy of ENDS to help smokers quit have been published so far. They have promising, yet inconclusive results, as the number of included participants were small. The safety and potential adverse effects of ENDS are also largely unknown. While the aerosol the users inhale appears safe in laboratory conditions, the difference in exposure to chemicals (such as reduction in exposure to volatile organic compounds) and effects of chemicals on the body (adverse events, improved health-related outcomes and measures of oxidative stress) between smokers who quit (with or without ENDS) and those who use ENDS for a long time have not yet been assessed in an RCT. This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and exposure to inhaled chemicals. The primary hypothesis of this trial is that providing cigarette smokers willing to quit smoking tobacco cigarettes with ENDS leads to a higher rate of smokers who quit cigarette smoking than only smoking cessation counseling with nicotine replacement therapy (NRT), which represents nowadays the standard of care. For this trial, cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. Participants in both groups will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. After 6,12 and 24 months, participants will be asked to come to a clinical visit.

Full Title of Study: “Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (The ESTxENDS Trial)- Extension of Follow-up”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 31, 2023

Interventions

  • Other: ENDS (vaporizer/e-cig) and smoking cessation counseling
    • Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
  • Other: Smoking cessation counseling
    • Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Arms, Groups and Cohorts

  • Experimental: Intervention group
  • Active Comparator: Control group

Clinical Trial Outcome Measures

Primary Measures

  • Validated 7-day point prevalence abstinence (1)
    • Time Frame: 12 months post quit date
    • Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO).
  • Validated 7-day point prevalence abstinence (1.1)
    • Time Frame: 24 months post quit date
    • Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO).
  • Validated 7-day point prevalence abstinence (2)
    • Time Frame: 12 months post quit date
    • Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO).
  • Validated 7-day point prevalence abstinence (2.1)
    • Time Frame: 24 months post quit date
    • Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO).

Secondary Measures

  • Self-reported 7-day point prevalence abstinence
    • Time Frame: 12, 24 months post quit date
    • Self-report of having smoked no cigarettes in the past seven days.
  • Continuous smoking abstinence
    • Time Frame: 12, 24 months post quit date
    • Self-report of having smoked no cigarettes from quit date, validated by urinary levels of anabasine. If anabasine is missing, validation by exhaled carbon monoxide (CO).
  • Continuous smoking abstinence (2)
    • Time Frame: 12, 24 months post quit date
    • Self-report of having smoked no cigarettes from quit date, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO).
  • Self-reported smoking abstinence allowing a 2-week’grace period’
    • Time Frame: 12, 24 months post quit date
    • Smoking abstinence allowing a 2-week’grace period’ after the target quit date.
  • Validated smoking abstinence allowing a 2-week’grace period’ (1)
    • Time Frame: 12, 24 months post quit date
    • Smoking abstinence allowing a 2-week’grace period’ after the target quit date, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO).
  • Validated smoking abstinence allowing a 2-week’grace period’ (2)
    • Time Frame: 12, 24 months post quit date
    • Smoking abstinence allowing a 2-week’grace period’ after the target quit date, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO).
  • Self-reported smoking abstinence allowing up to 5 cigarettes
    • Time Frame: 12, 24 months post quit date
    • Smoking abstinence allowing up to 5 cigarettes in total after the target quit date.
  • Validated smoking abstinence allowing up to 5 cigarettes (1)
    • Time Frame: 12, 24 months post quit date
    • Smoking abstinence allowing up to 5 cigarettes in total after the target quit date, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO).
  • Validated smoking abstinence allowing up to 5 cigarettes (2)
    • Time Frame: 12, 24 months post quit date
    • Smoking abstinence allowing up to 5 cigarettes in total after the target quit date, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO).
  • Number of cigarettes smoked per day (CPD)
    • Time Frame: 12, 24 months post quit date
    • self-reported
  • Change in number of cigarettes smoked per day (CPD)
    • Time Frame: 12, 24 months post quit date
    • self-reported.Successful reduction defined as 50% reduction in CPD.
  • Use of any other smoking cessation products (NRT, Nicotine replacement therapy)
    • Time Frame: 12, 24 months post quit date
    • self-reported on whether and how often they used any NRT.
  • Withdrawal
    • Time Frame: 12, 24 months post quit date
    • The physical signs and symptoms associated with withdrawal, measured using the Minnesota Tobacco Withdrawal Scale (http://www.med.uvm.edu/behaviorandhealth/minnwsdefault). The Minnesota Tobacco Withdrawal Scale measures self-reported severity of nicotine withdrawal. The measure has 15 items, with five possible responses (0-5), thus scores on the scale range from 0 to 60.
  • Nicotine dependence
    • Time Frame: 12, 24 months post quit date
    • Nicotine dependence measured using the Fagerström Test. The Fagerström Test for Nicotine Dependence (FTND, Heatherton TF et al., 1991) is a standard instrument for assessing the intensity of physical addiction to nicotine. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. Two items have four possible responses (0-3) and four items have two possible responses (0-1). The nicotine dependence score ranges from 0 to 10. A score between 0 and 2 is considered as a low nicotine dependence, a score between 3 to 5 is considered as a medium nicotine dependence, a score between 6 and 7 is considered as a high nicotine dependence and a score between 8 and 10 is considered as a very high nicotine dependence.
  • Health-related quality of life
    • Time Frame: 12, 24 months post quit date
    • Measured using the Swiss EQ-5D. The EQ-5D questionnaire is a standardized measure of health status developed by the EuroQol Group (https://euroqol.org/). EQ-5D questionnaires have five dimensions: “Mobility”, “Self-care,” “Usual Activities”, “Pain / Discomfort”, “Anxiety / Depression” and all dimensions are described by five problem levels corresponding to participant response choices.
  • Use of any ENDS
    • Time Frame: 12, 24 months post quit date
    • self-reported on whether and how often they used any ENDS
  • Report on most common adverse events using ENDS
    • Time Frame: 12, 24 months post quit date
    • Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of ENDS, whether or not it is considered related to the product.

Participating in This Clinical Trial

Inclusion Criteria

  • Informed Consent as documented by signature – Persons aged 18 or older – Currently smoking 5 or more cigarettes a day for at least 12 months – Willing to try to quit smoking within the next 3 months, – Persons providing a valid phone number, a valid email address and/or a valid postal address. Exclusion Criteria:

  • Known hypersensitivity or allergy to contents of the e-liquid Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected – Women who are pregnant or breast feeding – Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study – Persons having used ENDS regularly in the 3 months preceding the baseline visit – Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit – Persons who cannot attend the 6- month follow-up visit for any reason – Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Bern
  • Collaborator
    • University of Lausanne
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Reto Auer, Prof.Dr.med., Study Director, Berner Institut für Hausarztmedizin; Universität Bern

References

Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013 Nov 16;382(9905):1629-37. doi: 10.1016/S0140-6736(13)61842-5. Epub 2013 Sep 9.

Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013 Jun 24;8(6):e66317. doi: 10.1371/journal.pone.0066317. Print 2013. Erratum In: PLoS One. 2014;9(1). doi:10.1371/annotation/e12c22d3-a42b-455d-9100-6c7ee45d58d0.

Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2016 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub3.

Malas M, van der Tempel J, Schwartz R, Minichiello A, Lightfoot C, Noormohamed A, Andrews J, Zawertailo L, Ferrence R. Electronic Cigarettes for Smoking Cessation: A Systematic Review. Nicotine Tob Res. 2016 Oct;18(10):1926-1936. doi: 10.1093/ntr/ntw119. Epub 2016 Apr 25.

Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014 Apr;5(2):67-86. doi: 10.1177/2042098614524430.

Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27. doi: 10.1111/j.1360-0443.1991.tb01879.x.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.